Hansen J F, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Bjergaard O P
Department of Cardiology, Hvidovre University Hospital, Holstebra, Denmark.
Am Heart J. 1997 Aug;134(2 Pt 2):S48-52. doi: 10.1016/s0002-8703(97)70008-5.
In a double-blind, randomized trial in a consecutive group of postinfarct patients in treatment with diuretic agents for congestive heart failure, the 3 month rate of cardiac events (i.e., death, repeat infarction, unstable angina pectoris, or repeat admission because of heart failure) was 14% in patients treated with verapamil and trandolapril and 35% in patients treated with trandolapril (p = 0.01). In another study of patients with angina pectoris and left ventricular ejection fraction less than 40%, trandolapril plus verapamil improved exercise duration and left ventricular ejection fraction. These findings indicate that combined treatment with verapamil and trandolapril may be beneficial in patients with congestive heart failure.
在一项针对连续入选的心肌梗死后使用利尿剂治疗充血性心力衰竭患者的双盲随机试验中,接受维拉帕米和群多普利治疗的患者3个月内心脏事件(即死亡、再次梗死、不稳定型心绞痛或因心力衰竭再次入院)发生率为14%,而接受群多普利治疗的患者为35%(p = 0.01)。在另一项针对心绞痛且左心室射血分数低于40%患者的研究中,群多普利加维拉帕米可改善运动持续时间和左心室射血分数。这些发现表明,维拉帕米与群多普利联合治疗可能对充血性心力衰竭患者有益。